Mayo Clinic Senolytic Trial: Postmenopausal Women with High Senescent Burden Show +2.7% BMD

A Mayo Clinic team reported in Nature Medicine on a randomized trial of 60 postmenopausal women treated with the senolytic combination dasatinib + quercetin (D+Q). It’s the first randomized controlled trial testing whether senolytics, drugs that selectively target senescent cells, can affect human bone health.

Senolytics, drugs that clear senescent cells

Senolytics selectively eliminate senescent cells: cells that have stopped dividing but resist death and secrete inflammatory signals. Dasatinib is a kinase inhibitor used in leukemia treatment; quercetin is a flavonoid found in onions and apple skins. The D+Q combination is the most-studied senolytic regimen.

In postmenopausal women, estrogen decline accelerates bone resorption, and senescent cells accumulate in bone tissue. The hypothesis: SASP (senescence-associated secretory phenotype) factors stimulate bone resorption, so removing senescent cells should slow bone loss.

60 women, 20 weeks intermittent dosing

The trial randomized 60 postmenopausal women (mean age 71) to D+Q (two consecutive days per month, 5 cycles over 20 weeks) or placebo.

The primary endpoint was 20-week change in bone resorption marker CTx. No difference vs placebo. The primary endpoint missed.

But the bone formation marker P1NP showed an interesting pattern. +16% at week 2 (P=0.020), +16% at week 4 (P=0.024). A short-term signal of bone formation activation.

Meaningful difference in the high-senescent-burden subgroup

The key finding came from a prespecified subgroup analysis. Researchers measured T cell p16 mRNA expression (a senescent burden marker) and analyzed the highest tertile separately.

In this subgroup, P1NP rose +34% at week 2 (P=0.035), CTx dropped -11% (P=0.049). For the first time, both bone formation up and bone resorption down was observed.

At week 20, distal radius bone mineral density (BMD) increased +2.7% (P=0.004). A meaningful difference vs placebo.

First signal for “personalized senolytics”

The message from this data: senolytics don’t work for everyone. They work for people with high senescent cell burden.

This has two implications. First, future trial designs need patient selection (measuring p16 or similar markers). Second, future osteoporosis treatment may evolve from bisphosphonate-only (resorption inhibition) toward dual-target combinations adding senolytic agents.

Self-prescribing is dangerous

Dasatinib is a prescription drug (Sprycel and others, used in leukemia) with known side effects. Self-administration is dangerous. Quercetin is sold as a supplement, but evidence for monotherapy effects is weak.

Next steps

Researchers are planning larger (hundreds of patients) and longer (2+ years) follow-up trials. Other senolytic combinations (fisetin, navitoclax) are also in clinical stages. A senolytic drug category for age-related conditions is likely to take shape over the next 5-10 years.

Combined with this quarter’s NMN, NR, and NAD+ booster trends, age-mechanism-targeting drugs and supplements are forming a category quickly. Bone health is the largest health variable for postmenopausal women, and senolytics could become a new option distinct from hormone replacement therapy (HRT).

What consumers can do now. Calcium, vitamin D3, vitamin K2 (MK-7), adequate protein, resistance training. These fundamentals remain the most reliable foundation for bone health until senolytics enter formal clinical practice.